ALL
Pharma in China
Pharma Experts
Market News
Products Guide
Brand Story
-
Gene therapy drug Kymriah should be publicly covered if manufacturer drops price, report recommends
January 17, 2019An expert panel convened by the Canadian Agency for Drugs and Technologies in Health (CADTH) concluded that Novartis' gene therapy Kymriah should be publicly covered provided the company lowers its price, The Globe and Mail reported. -
Gene therapy drug Kymriah should be publicly covered if manufacturer drops price, report recommends
January 17, 2019An expert panel convened by the Canadian Agency for Drugs and Technologies in Health (CADTH) concluded that Novartis' gene therapy Kymriah should be publicly covered provided the company lowers its price, The Globe and Mail reported.
Pharma Sources Insight January 2025
